DS Biopharma receives a patent allowance for Oral DS107 in the US

Dublin, Ireland, April 13th, 2017 – DS Biopharma (DS), a clinical stage biopharmaceutical company, today announced receipt of allowance for a patent application in the United States of America (US). The allowance protects oral compositions of the Company’s lead compound DS107.

The United States Patent and Trademark Office (USPTO) has allowed the US patent application entitled “Pharmaceutical composition comprising DGLA and use of the same” which has the serial number 14/730,818. This will provide exclusivity for oral compositions of DS107 until 2035.

DS continues to prosecute additional patent applications for both topical and oral DS107 in the US and other key jurisdictions.

About DS Biopharma

DS Biopharma, headquartered in Dublin, Ireland, is a privately held, clinical stage, pharmaceutical drug discovery and development company, which develops new medicines for unmet needs in dermatological diseases. The compounds under development are based on a novel bioactive lipid platform. These lipid molecules have been shown to be crucial to the pathways of several conditions including skin disorders such as atopic dermatitis (AD), acne and psoriasis. The Company has two separate Phase 2b trials recruiting in North America at present: topical DS107 in 300 mild to moderate AD patients and oral DS107 in 300 moderate to severe AD patients.



DS Biopharma: investorrelations@dsbiopharma.com, +35312933590